84126-69-2

Usage

InChI:InChI=1/C9H17NO2.ClH/c1-2-12-9(11)7-10-8-5-3-4-6-8;/h8,10H,2-7H2,1H3;1H

Upstream product

• 89479-61-8 N-cyclopentylglycine ethyl ester 
• 1003-03-8 Cyclopentamine 
• 623-33-6 glycine ethyl ester hydrochloride 
• 120-92-3 cyclopentanone 

Downstream Products

• 126380-81-2 N-α-(1-carbethoxy-3-phenylpropyl)-N^ε-benzyloxycarbonyl-L-lysyl>-N-cyclopentyl glycine 
• 126333-45-7 N-α-(1-carbethoxy-3-cyclohexylpropyl)-N^ε-benzyloxycarbonyl-L-lysyl>-N-cyclopentyl glycine 
• 94739-05-6 N-α-(1-carboxy-3-phenylpropyl)-N^ε-benzyloxycarbonyl-L-lysyl>-N-cyclopentyl glycine 
• 126380-84-5 N-(N^α-tert-butoxycarbonyl-N^ε-carbobenzoxy-L-lysyl)-N-cyclopentyl glycine 
• 94739-04-5 N-(N^ε-carbobenzoxy-L-lysyl)-N-cyclopentyl glycine 
• 126333-41-3 N-α-(1-carboxy-3-cyclohexylpropyl)-N^ε-benzyloxycarbonyl-L-lysyl>-N-cyclopentyl glycine 
• 120285-32-7 N-α-(1-carboxy-3-cyclohexylpropyl)-L-lysyl>-N-cyclopentyl glycine 
• 126333-57-1 N-(N^α-tert-butoxycarbonyl-N^ε-carbobenzoxy-L-lysyl)-N-cyclopentyl glycine ethyl ester 

Relevant academic research and scientific papers

CYCLIN-DEPENDENT KINASE INHIBITORS

Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.

Antiviral phosphoramidates

The invention provides novel nucleoside compounds of formula I wherein R1, R2a, R2b, R3, R4, R5, R6, R8a, R9 and R10 are as defined herein which are useful for the treatment of Hepatitis C Virus (HCV) mediated diseases. The invention further provides methods for treatment or prophylaxis of HCV mediated diseases with compounds of formula I and pharmaceutical compositions comprising these compounds,

Synthesis and angiotensin converting enzyme inhibitory activity of L-lysyl-N-substituted glycine derivatives

The synthesis and biological activity of novel L-lysyl-N-substituted glycine derivatives which exhibit in vitro and in vivo angiotensin converting enzyme (ACE) inhibition, are described. Particularly, N-[N(α)-(1-carboxy-3-phenylpropyl)-L-lysyl]-N-(4-pheny